- Home
- EE vs MDXG Comparison
EE vs MDXG Comparison
Compare EE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EE | MDXG |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.1M | 1.0B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | EE | MDXG |
|---|---|---|
| Price | $26.41 | $7.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $33.43 | $12.00 |
| AVG Volume (30 Days) | 360.3K | ★ 774.9K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 51.11 | N/A |
| EPS | ★ 1.42 | 0.27 |
| Revenue | ★ $1,185,262,000.00 | $393,442,000.00 |
| Revenue This Year | $40.00 | $19.13 |
| Revenue Next Year | $27.68 | $2.11 |
| P/E Ratio | ★ $19.18 | $26.77 |
| Revenue Growth | ★ 45.09 | 14.77 |
| 52 Week Low | $21.29 | $5.79 |
| 52 Week High | $32.99 | $9.71 |
Technical Indicators
Market Signals| Indicator | EE | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 56.81 |
| Support Level | $26.74 | $6.62 |
| Resistance Level | $28.05 | $7.30 |
| Average True Range (ATR) | 0.76 | 0.24 |
| MACD | -0.20 | 0.05 |
| Stochastic Oscillator | 1.01 | 93.48 |
Price Performance
Historical ComparisonAbout EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.